TL;DR
- •Sublingual ketamine at therapeutic doses produces a gentle altered-perception state — most patients describe it as soft, curious, and time-limited rather than intense or frightening.
- •Common sensations: softness or floating in the body, gentle visual changes (more vivid colors, geometric patterns with closed eyes), distance from immediate concerns, sometimes profound feelings of compassion or connection.
- •The dissociation isn't about losing yourself — most patients describe it as feeling spaciousness around themselves rather than disappearance of self.
- •Difficult emotions can surface — sadness, grief, anger — and that's sometimes part of the therapeutic effect rather than a problem. Skilled integration afterward helps these become useful rather than distressing.
- •The day after often feels gentle, reflective, sometimes raw — many patients describe feeling more emotionally available than usual for 24-72 hours.
- •Sublingual ketamine is distinctly different from recreational ketamine ("Special K") — therapeutic doses don't produce the K-hole state; the experience is calibrated for psychotherapeutic effect rather than dissociative intensity.
Step by step
- 1
First 15 minutes — onset
Subtle softening of body sensations. Some patients notice colors becoming more saturated or sounds becoming more musical. Slight floating quality. Many patients describe the onset as "permission to relax" — the body knows something is happening.
- 2
30-45 minutes — peak
Most pronounced sensations. With eye mask on: geometric patterns, fractal imagery, sometimes vivid color experiences. Sense of distance from usual mental patterns. Time can feel stretched or compressed. Music feels embodied. Many patients describe the peak as the part where insights or emotional movement happens.
- 3
60-90 minutes — return
Dissociative effect fades. Body returns. Ability to talk, walk around, drink water. Most patients describe feeling gentle, soft, sometimes emotional. Tears are not uncommon during this phase — often described as the body releasing held emotion.
- 4
Evening of the session
Quiet, reflective. Many patients describe feeling more emotionally present and less defended than usual. Some patients have profound experiences of compassion or self-acceptance. Sleep is typically deep with vivid dreams.
- 5
Day after
Most patients return to normal cognitive function. Some describe a "honeymoon" feeling — depression quieter, mood lighter, emotional range fuller. This is the rapid antidepressant response — sometimes the day-after is the most-changed day.
What this actually feels like
The most common description: gentle, curious, time-limited. Patients often describe their usual mental patterns (rumination, self-criticism, anxious anticipation) becoming temporarily quiet — not absent, but less central. Many describe an "observer self" — a sense of watching their own thoughts and feelings with less attachment. Visual experiences range from minimal (some patients have essentially no visual changes) to vivid (geometric patterns, color experiences, occasional brief imagery). Music is often deeply moving during the peak. Difficult emotions can surface and feel cleansing rather than overwhelming when held within the supported session structure. Body sensations are mostly pleasant or neutral — some patients feel heavy and grounded; others feel floating and light. The experience is interior — most patients prefer eyes closed and silence around them.
Timeline
A single session: 15 min onset → 30-45 min peak → 60-90 min recovery. Total session time including check-in and integration: 1.5-2 hours. Effect resolves by bedtime. Day-after typically feels gentle and reflective. The post-session "honeymoon" of clearer mood and lighter depression typically lasts 3-7 days early in treatment, building duration as sessions continue.
Common concerns, addressed
“Will I feel "out of my body" or lose touch with reality?”
Therapeutic sublingual ketamine produces a contained, time-limited dissociation — not the K-hole intensity of recreational doses. You can hear the room, talk if you need to, walk to the bathroom. The experience feels more like deep meditation than psychedelic intensity for most patients.
“What if I have a terrifying experience?”
Difficult moments happen but they're typically meaningful in retrospect rather than damaging. Preparation matters: comfortable environment, prepared music, supportive setting, intention-setting before the session. Tovani's preparation protocols significantly reduce the chance of a difficult experience and provide integration support if one does occur.
“I've done psychedelics — is this similar?”
Sublingual ketamine at therapeutic doses is gentler and shorter than psychedelic experiences. The duration is 60-90 minutes vs 4-8 hours for psilocybin or LSD. The intensity is less. The dissociative mechanism is different from the serotonergic psychedelic mechanism. Some patients describe the experience as "psychedelic-adjacent" rather than fully psychedelic.
“I'm sensitive to medications — will this be too much?”
Sensitivity is addressable through dose adjustment. Many patients start at lower doses than the protocol target and titrate up across sessions if needed. Your physician adjusts based on your specific experience. The dose isn't fixed — it's individualized.
“What if I cry the whole time?”
Sometimes happens — and often it's exactly the therapeutic moment. Tears during a session are common and frequently described as cleansing. The session structure (supportive environment, integration afterward) makes emotional release useful rather than overwhelming.
Who this fits best
The sublingual ketamine experience is most accessible to patients who: are comfortable with introspective experiences (meditation, journaling, therapy backgrounds help), can arrange a supportive environment (quiet space, someone in the home, prepared music), and have realistic expectations (this is not a quick fix or a recreational experience). Patients with significant trauma histories benefit from extra preparation; the experience can surface trauma material that's best processed with specialist trauma support alongside the medication treatment.
Ready to start?
Tovani offers board-certified telehealth ketamine therapy for treatment-resistant depression, anxiety, PTSD, and chronic pain. Available in Florida and New Jersey.
Check eligibility5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
Will I see things during the session?
Many patients see gentle visual changes — geometric patterns, color experiences, fractal imagery — with the eye mask on. Some patients have minimal visual experience. The visual dimension varies; it's not the central therapeutic element. The mood-and-cognitive shift is more important than the visual content.
Will I remember the session?
Yes, mostly. Memory of the session is generally intact, though some details can feel dreamlike afterward. Many patients journal immediately after to capture impressions before they fade. The integration check-in helps consolidate what was meaningful.
Can I talk during the session?
You can but most patients prefer not to. Words feel unreliable during the peak. Your care team is reachable if you need support, but most sessions are interior — eyes closed, headphones on, music as the primary external input.
What if I don't like the experience?
Subjective preference for the experience and clinical response are different. Some patients have neutral or mildly unpleasant experiences and respond beautifully clinically. The goal isn't a pleasant trip; it's effective treatment of depression / anxiety / PTSD. If the experience itself is consistently difficult, dose adjustment or environmental optimization usually helps — but a quiet, unspectacular session can still be the right kind of session.
How is this different from recreational ketamine?
Therapeutic doses (much lower than recreational), supervised setting, structured preparation and integration, music and eye mask creating an interior experience, clinical follow-up, and embedded in a treatment plan rather than isolated use. The mechanism is the same (NMDA antagonism); the application and effect are entirely different. Recreational use is associated with addiction, urological issues, and cognitive harm; therapeutic use under supervision is associated with rapid antidepressant response and low complication rates.
References
- Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT in treatment-resistant depression — characterized the dissociative experience as part of the protocol; did not predict response. PMID 23982301
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus on ketamine in mood disorders — discusses the subjective experience and clinical considerations for patient preparation. PMID 28249076